menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Geron Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    Geron Corporation Announces Departure of Chief Executive Officer

    BUSINESSWIRE

    Geron Gets EC Approval For RYTELO In Lower-Risk MDS Anemia

    BUSINESSWIRE

    Geron Reports Q4, Full-Year 2024 Results & Business Updates

    BUSINESSWIRE

    Geron to Participate at Upcoming Investor Conferences in March 2025

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Geron to Announce Q4 & Full-Year 2024 Financial Results on Feb 26

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    Geron`s RYTELO™ Approved By CHMP For Transfusion-Dependent MDS

    BUSINESSWIRE

    Geron: IMerge Data Shows RYTELO™ Active In Lower-Risk MDS

    BUSINESSWIRE

    Geron to Participate in Evercore ISI HealthCONx Conference

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    Geron to Participate in Stifel 2024 Healthcare Conference

    BUSINESSWIRE

    Geron Appoints Joseph Eid, M.D. as EVP of R&D

    BUSINESSWIRE

    Geron Corporation Reports Q3 2024 Financial Results & Highlights

    BUSINESSWIRE

    Geron Corporation Announces $375M in Funding with Royalty Pharma

    BUSINESSWIRE

    Geron to Present RYTELO™ Data at ASH in Hematologic Malignancies

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron to Announce Third Quarter 2024 Financial Results on Nov 7, 2024

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule

    BUSINESSWIRE

    Geron Corp Names Jim Ziegler As Chief Commercial Officer

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron Corporation Reports Q2 2024 Results And Business Highlights

    BUSINESSWIRE

    NCCN Guidelines Now Include Geron`s RYTELO For Lower-Risk MDS Treatment

    BUSINESSWIRE

    Geron Announces Chief Commercial Officer`s Departure In August 2024

    BUSINESSWIRE

    Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    FDA signs off on Geron`s long-awaited blood cancer drug Rytelo

    FIERCE PHARMA

    Geron`s RYTELO™ Telomerase Inhibitor Approved For Lower-Risk MDS

    BUSINESSWIRE

    Geron Announces FDA Approval Of RYTELO™ For Treatment Of Lower-Risk MDS

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually

    ENDPTS

    Geron Reports Q1 2024 Results, Business Highlights

    BUSINESSWIRE

    Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron to Participate at Upcoming Investor Conferences in April

    BUSINESSWIRE

    Geron Corporation Announces Pricing of $150 M Underwritten Offering of

    BUSINESSWIRE

    Geron secures 12-2 AdComm vote in favor of blood cancer drug

    FIERCE BIOTECH

    Geron`s blood disorder drug gets FDA advisers` backing

    YAHOO FINANCE

    US FDA staff raises concerns on Geron`s blood disorder drug

    REUTERS

    Geron Reports Fourth Quarter and Full Year 2023 Financial Results

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron to Participate in the B. Riley Securities Virtual Oncology Conference

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron Announces IMerge Phase 3 Presentations at ASH

    BUSINESSWIRE

    Geron Announces 50% Enrollment in the Phase 3 Trial Evaluating Imetelstat

    BUSINESSWIRE

    Geron Announces Publication of Results from Phase 3 Evaluating Imetelstat

    BUSINESSWIRE

    Geron Announces Appointment of Gaurav Aggarwal to its Board of Directors

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron to Participate at Upcoming Investor Conferences in November

    BUSINESSWIRE

    Geron Reports Business Highlights and Third Quarter 2023 Financial Results

    BUSINESSWIRE

    Geron IMerge Phase 3 Presentations Reinforce Durability of Imetelstat

    BUSINESSWIRE

    Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

    BUSINESSWIRE

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Geron Announces EMA Validation of MAA for Imetelstat

    BUSINESSWIRE

    Geron Announces Appointment of Michelle Robertson as Executive Vice President

    BUSINESSWIRE

    Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.